- Published at
- by investing.com
mixed
mixed
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA ® (pembrolizumab) for the Treatment of Advanced Bladder Cancer By Investing.com
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA ® (pembrolizumab) for the Treatment of Advanced Bladder Cancer